H. Schwenke

Impact of modified-release prednisone on functional ability in patients with rheumatoid arthritis

B. Pfeiffer, Stefanie Krenzer, R. Schwenke, 2013, Rheumatology International.

Ustekinumab Is Rapid-Acting and Is an Effective Long-Term Treatment for Patients with Active Psoriatic Arthritis: Real-World Evidence from the Non-interventional SUSTAIN Study

J. Wendler, F. Behrens, M. Schuier, 2022, Rheumatology and Therapy.

AB0520 Tocilizumab in rheumatoid arthritis – one year interim analysis of the non-interventional ichiban study

M. Aringer, H. Kellner, H. Tony, 2013 .

Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial

S. Wassenberg, E. Herrmann, T. Rossmanith, 2023, The Lancet Rheumatology.

Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience

Uwe Pichlmeier, Ulf Müller-Ladner, U. Müller-Ladner, 2014, Patient preference and adherence.

Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial

M. Dougados, G. Burmester, F. Buttgereit, 2020, The Lancet.

ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.

G. Burmester, I. Gürtler, M. Peters, 2016, Rheumatology.

Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI).

G. Burmester, T. Dörner, H. Schulze-Koops, 2019, Clinical and experimental rheumatology.